Allogene is a clinical-stage biopharmaceutical company developing allogeneic, or "off-the-shelf," CAR T cell therapies — engineered immune cells manufactured in advance from healthy donors and shipped to patients on demand. Unlike autologous CAR T therapies (made individually from each patient's own cells, a process taking weeks), Allogene's approach produces roughly 100+ doses per donor run, enabling rapid delivery and broader access, including at community cancer centers. Allogene's lead program, cema-cel, targets CD19 on malignant B cells and is being evaluated in a pivotal trial (ALPHA3) for first-line consolidation in large B-cell lymphoma patients who are MRD-positive after chemotherapy — a setting with no approved therapy. An interim futility readout is expected in April 2026. ALLO-329, a next-generation dual CD19/CD70 product incorporating Allogene's proprietary "Dagger" technology, is in Phase 1 trials for autoimmune diseases including lupus and systemic sclerosis, with initial data expected in June 2026. ALLO-316 targets CD70 in renal cell carcinoma and holds FDA RMAT designation; Allogene is seeking a partner to fund its development. The company has no approved products or product revenue, and funds operations through capital markets. Allogene operates its own manufacturing facility in Newark, CA, and holds a licensing arrangement covering Greater China, Korea, and Singapore through a joint venture.